GALILEO ONCOLOGICS is an Italian biotechnology company with a full pipeline of anti-neoplastic projects at different stages of development, ranging from the preclinical stage to Phase II clinical testing, associated with an extensive package of Intellectual Property. GALILEO ONCOLOGICS has been established in 2008 and originates from Abiogen Pharma S.p.A, a well established Italian pharmaceutical company, who has actively continued the development of these projects.
Existing partnerships are with key collaborators at the University of Texas Southwestern Medical School and the Wistar Institute in Philadelphia and represent the foreground for such targeted technologies as effective platforms for the treatment of a variety of cancers.
Founders include personnel from Abiogen as well as some of the academic scientists who originated the work:
Alberto Bresci - Silvia Trasciatti (Abiogen Pharma)
Ellen Vitetta and John Schindler (University of Texas Southwestern)
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.abiogen.it
- Keywords
- Biotechnology Research.
Galileo Research Questions
Galileo Research's website is http://www.abiogen.it
Galileo Research's LinkedIn profile is https://it.linkedin.com/company/galileo-research
Galileo Research's industry is
Biotechnology Research
Galileo Research's top competitors are
Biorep,
Abiogen Pharma S.p.a.,
Transactiva Srl,
Iga Technology Services,
Farmigea,
Vivabiocell,
Mttlab Srl,
Alifax,
Laboratori Baldacci Spa,
Galileo Research Srl.
Galileo Research's categories are Biotechnology Research
